Most Read Articles
Jairia Dela Cruz, 4 days ago
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
5 days ago
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.

Product Highlight - Spiolto Respimat

01 May 2018
SPIOLTO RESPIMAT - Tiotropium 2.5 mcg, Olodaterol 2.5 mcg inhalation soln - Boehringer Ingelheim

The Only LAMA/LABA with the active ingredient of SPIRIVA inside (Tiotropium)
Start SPIOLTO RESPIMAT early for your patients
• Starts working within 5 minutes after the first dose1
• Improves lung function, lasts for 24 hours1,2
• Consistently reduces the need for rescue medication beyond SPIRIVA7
• Contains SPIRIVA which has unsurpassed long-term data in EXACERBATION3
• Respimat is designed for deep lung deposition4-6 and all your patients need to do
  is breathe in naturally7

References:
1. SPIOLTO RESPIMAT Summary of Product Characteristics, March 2016
2. Beeh KM. Pulm Pharmacol Ther 2015;32:53-59.
3. Tashkin DP, et al. N Engl J Med 2008;21:159-168.
4. Newman SP, et al. Chest 1998;113:957-963
5. Pitcairn G, et al. J Aerosol Med 2005;18:264-272.
6. Peterson JB, et al. J Aerosol Med Pulm Drug Del 2008;21:159-168.
7. SPIRIVA RESPIMAT Summary of Product Characteristics, Nov 2017

Further information is available in section 3b and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 4 days ago
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
5 days ago
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.